Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Rltpr Is a Central Scaffold Protein Regulating Human TCR Co-Signaling and Cytoskeletal Dynamics

Tilmann Schober, MD, Thomas Magg, PhD, Melanie Laschinger, PhD, Thomas Fröhlich, PhD, Meino Rohlfs, PhD, Yanshan Liu, PhD, Jacek Puchalka, PhD, Tanja Weisser, Karin Fehlner, PhD, Christoph Walz, MD, Natália Duarte Linhares, PhD, Sérgio D. Pena, MD PhD, Bernd H. Belohradsky, MD, Christoph Klein, MD PhD, Fabian Hauck, MD PhD

Blood (2016) 128 (22): 131.

https://doi.org/10.1182/blood.V128.22.131.131

Published: 2016

Journal Articles

A Human Bone Marrow Failure Syndrome Caused By a Homozygous Mutation in MYSM1

Ehsan Bahrami, Tomas Racek, PhD, Maximilian Witzel, MD, Jacek Puchalka, PhD, Naschla Greif-Kohistani, MD, Daniel Kotlarz, MD PhD, Michael Orth, PhD, Kirsten Lauber, PhD, Christoph Walz, MD, Waleed Al Herz, MD, Hans-Peter Horny, MD, Heinrich Schmidt, MD, Michael H. Albert, MD, Christoph Klein, MD PhD

Blood (2015) 126 (23): 1204.

https://doi.org/10.1182/blood.V126.23.1204.1204

Published: 2015

Journal Articles

Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event

Mohamad Jawhar, MD, Juliana Schwaab, MD, Susanne Schnittger, PhD, Karl Sotlar, MD, Hans Peter Horny, MD, Georgia Metzgeroth, Sven Schneider, MD, Nadine Müller, Nicole Naumann, Christoph Walz, MD, Torsten Haferlach, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Alice Fabarius, PhD, Andreas Reiter, MD

Blood (2014) 124 (21): 3216.

https://doi.org/10.1182/blood.V124.21.3216.3216

Published: 2014

Journal Articles

Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis

Blood (2013) 122 (21): 4094.

https://doi.org/10.1182/blood.V122.21.4094.4094

Published: 2013

Journal Articles

Comprehensive mutational profiling in advanced systemic mastocytosis

Blood (2013) 122 (14): 2460–2466.

https://doi.org/10.1182/blood-2013-04-496448

Published: 2013

Includes: Supplemental data

Journal Articles

JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1 + chronic myeloid leukemia

Wolfgang Warsch, Christoph Walz, Veronika Sexl

Blood (2013) 122 (13): 2167–2175.

https://doi.org/10.1182/blood-2013-02-485573

Published: 2013

Journal Articles

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2 V617F in mice

Christoph Walz, Wesam Ahmed, Katherine Lazarides, Monica Betancur, Nihal Patel, Lothar Hennighausen, Virginia M. Zaleskas, Richard A. Van Etten

Blood (2012) 119 (15): 3550–3560.

https://doi.org/10.1182/blood-2011-12-397554

Published: 2012

Includes: Supplemental data

Journal Articles

Response of ETV6-FLT3 –positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3

Christoph Walz, Philipp Erben, Michael Ritter, Adrian Bloor, Georgia Metzgeroth, Nick Telford, Claudia Haferlach, Torsten Haferlach, Stefan Gesk, Joannah Score, Wolf-Karsten Hofmann, Andreas Hochhaus, Nicholas C. P. Cross, Andreas Reiter

Blood (2011) 118 (8): 2239–2242.

https://doi.org/10.1182/blood-2011-03-343426

Published: 2011

Includes: Supplemental data

Journal Articles

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease

Christian Elling, Philipp Erben, Christoph Walz, Marie Frickenhaus, Mirle Schemionek, Martin Stehling, Hubert Serve, Nicholas C. P. Cross, Andreas Hochhaus, Wolf-Karsten Hofmann, Wolfgang E. Berdel, Carsten Müller-Tidow, Andreas Reiter, Steffen Koschmieder

Blood (2011) 117 (10): 2935–2943.

https://doi.org/10.1182/blood-2010-05-286757

Published: 2011

Journal Articles

KIT D816V and JAK2 V617F Point Mutations Are Recurrently Found In Suspected Hypereosinophilic Syndrome

Juliana Popa, MD, Philipp Erben, MD, Georgia Metzgeroth, MD, Georg Bolz, MD, Martin C Mueller, MD, Christoph Walz, MD, Hans Peter Horny, MD, Philipp Ströbel, MD, Alexander Marx, MD, Nicholas C.P. Cross, PhD, FRCPath, Andreas Hochhaus, Wolf-Karsten Hofmann, MD, Andreas Reiter, MD

Blood (2010) 116 (21): 4100.

https://doi.org/10.1182/blood.V116.21.4100.4100

Published: 2010

Journal Articles

Novel PDGFRA Point Mutations in Hypereosinophilic Syndrome Induce Growth Factor Independence and Leukemia in Vitro and In Vivo.

Christian Elling, Philipp Erben, MD, Christoph Walz, MD, Marie Frickenhaus, Mirle Schemionek, PhD, Martin Stehling, PhD, Hubert Serve, MD, PhD, Nick C.P. Cross, PhD, Wolfgang Berdel, MD, Carsten Mueller-Tidow, MD, Andreas Reiter, MD, Steffen Koschmieder, MD

Blood (2009) 114 (22): 767.

https://doi.org/10.1182/blood.V114.22.767.767

Published: 2009

Journal Articles

Essential Role for Stat5a/b in Myeloproliferative Neoplasms Induced by BCR-ABL1 and Jak2 V617F.

Christoph Walz, MD, Katherine Lazarides, Nihal Patel, Lothar Hennighausen, PhD, Virginia M. Zaleskas, MD, Richard A. Van Etten, MD, PhD

Blood (2009) 114 (22): 312.

https://doi.org/10.1182/blood.V114.22.312.312

Published: 2009

Journal Articles

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

Richard A. Van Etten, MD, PhD, Wayne W. Chan, BA, Virginia M. Zaleskas, MD, Christoph Walz, MD, Peter Evangelista, BA, Katherine Lazarides, BS, Monica Betancur, MS, Scott Wise, MS, Peter A. Petillo, PhD, Daniel L. Flynn, PhD

Blood (2008) 112 (11): 576.

https://doi.org/10.1182/blood.V112.11.576.576

Published: 2008

Journal Articles

Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia

Margret S Rodrigues, PhD, Mamatha M Reddy, Christoph Walz, MD, Ravi Salgia, Klaus Podar, Hamid Band, Andreas Reiter, MD, James D Griffin, Martin Sattler

Blood (2008) 112 (11): 2948.

https://doi.org/10.1182/blood.V112.11.2948.2948

Published: 2008

Journal Articles

Characterization of Three New Fusion Genes Generated by Disruption of PDGFRB in Eosinophilia-Associated Chronic Myeloproliferative Neoplasms

Philipp Erben, MD, Darko Gosenca, PhD, Christoph Walz, MD, Georgia Metzgeroth, MD, Claudia Haferlach, MD, Martin C. Müller, MD, Andreas Hochhaus, MD, Nicholas C.P. Cross, PhD, Andreas Reiter, MD

Blood (2008) 112 (11): 3719.

https://doi.org/10.1182/blood.V112.11.3719.3719

Published: 2008

Journal Articles

The Jak2 V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

Gerlinde Wernig, Jeffrey R. Gonneville, Brian J. Crowley, Margret S. Rodrigues, Mamatha M. Reddy, Heidi E. Hudon, Christoph Walz, Andreas Reiter, Klaus Podar, Yohan Royer, Stefan N. Constantinescu, Michael H. Tomasson, James D. Griffin, D. Gary Gilliland, Martin Sattler

Blood (2008) 111 (7): 3751–3759.

https://doi.org/10.1182/blood-2007-07-102186

Published: 2008

Journal Articles

Complete Hematologic Response to Sunitinib in an Eosinophilia-Associated Chronic Myeloproliferative Disorder with an ETV6-FLT3 Fusion Gene.

Christoph Walz, MD, Michael Ritter, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD, Christoph Schulte, MD, Torsten Haferlach, MD, PhD, Georgia Metzgeroth, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD, Nicholas C.P. Cross, PhD, Andreas Reiter, MD

Blood (2007) 110 (11): 3558.

https://doi.org/10.1182/blood.V110.11.3558.3558

Published: 2007

Journal Articles

Association between Polymorphic Variation at the IL5RA Locus and the Severity of FIP1L1-PDGFRA Positive Chronic Eosinophilic Leukaemia

Sonja Burgstaller, MD, Sebastian Kreil, MD, Katherine Waghorn, BSc, Georgia Metzgeroth, MD, Claude Preudhomme, PhD, Katerina Zoi, PhD, Helen White, PhD, Daniela Cilloni, PhD, Christine Zoi, MD, Finella Brito-Babapulle, MD, Christoph Walz, MD, Andreas Reiter, MD, Nicholas C.P. Cross, PhD

Blood (2007) 110 (11): 1544.

https://doi.org/10.1182/blood.V110.11.1544.1544

Published: 2007

Journal Articles

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA –positive chronic eosinophilic leukemia

Blood (2007) 109 (11): 4635–4640.

https://doi.org/10.1182/blood-2006-10-050054

Published: 2007

Includes: Supplemental data

Journal Articles

A Phase-II-Study To Evaluate Efficacy and Safety of Imatinib in Eosinophilia-Associated Myeloproliferative Disorders and Idiopathic Hypereosinophilic Syndrome.

Georgia Metzgeroth, MD, Helena Popp, Christoph Walz, MD, Philipp Erben, MD, Jürgen Mix, Martin C. Müller, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD, Andreas Reiter, MD

Blood (2006) 108 (11): 671.

https://doi.org/10.1182/blood.V108.11.671.671

Published: 2006

NARROW

Rltpr Is a Central Scaffold Protein Regulating Human TCR Co-Signaling and Cytoskeletal Dynamics

A Human Bone Marrow Failure Syndrome Caused By a Homozygous Mutation in MYSM1

Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event

Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis

Comprehensive mutational profiling in advanced systemic mastocytosis

JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1 + chronic myeloid leukemia

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2 V617F in mice

Response of ETV6-FLT3 –positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease

KIT D816V and JAK2 V617F Point Mutations Are Recurrently Found In Suspected Hypereosinophilic Syndrome

Novel PDGFRA Point Mutations in Hypereosinophilic Syndrome Induce Growth Factor Independence and Leukemia in Vitro and In Vivo.

Essential Role for Stat5a/b in Myeloproliferative Neoplasms Induced by BCR-ABL1 and Jak2 V617F.

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia

Characterization of Three New Fusion Genes Generated by Disruption of PDGFRB in Eosinophilia-Associated Chronic Myeloproliferative Neoplasms

The Jak2 V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

Complete Hematologic Response to Sunitinib in an Eosinophilia-Associated Chronic Myeloproliferative Disorder with an ETV6-FLT3 Fusion Gene.

Association between Polymorphic Variation at the IL5RA Locus and the Severity of FIP1L1-PDGFRA Positive Chronic Eosinophilic Leukaemia

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA –positive chronic eosinophilic leukemia

A Phase-II-Study To Evaluate Efficacy and Safety of Imatinib in Eosinophilia-Associated Myeloproliferative Disorders and Idiopathic Hypereosinophilic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only